Anticoagulant, Prophylaxis, Treatment, Venous Thromboembolism
Conditions
Brief summary
DANHEP is a cluster randomized study of two different low molecular weight heparins. Parenteral anticoagulants are used in a variety of settings, including treatment and prevention of venous thromboembolism in cancer patients, medical patients, and surgical patients, along with the use as adjuvant therapy for coronary syndromes. The most frequently used parenteral anticoagulants in Denmark, include the two different low molecular weight heparins; dalteparin and tinzaparin. The two drugs are considered equally efficient and safe regarding treatment and prevention of thrombosis and risk of bleeding. Importantly, there is a lack of evidence regarding whether these drugs are in fact comparable. The aim of this study is therefore to investigate the comparative safety and efficacy of the two different low molecular weight heparins (dalteparin and tinzaparin using cluster randomization in patients with an indication for low molecular weight heparins.
Interventions
DRUGDalteparin Prefilled Syringe
Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
DRUGTinzaparin profiled syringe
Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
Sponsors
Herlev Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All patients with indication for low molecular weight heparin
Exclusion criteria
* Patients under the age of 18 * Patients who are incapable of understanding the written material received * Patients who after being informed in writing chooses not to participate * Patients with contraindications for low molecular weight heparins as described in the SmPC
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 30-day all-cause mortality and bleeding requiring blood transfusion | 30 days | To evaluate whether treatment with any of the low molecular weight heparins will increase the risk of bleeding requiring blood transfusion during admission or death within 30 days in patients with indication for low molecular weight heparins. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Blood transfusion during admission | 90 days | Blood transfusion defined from use of blood products |
| 90 day risk of pulmonary embolism | 90 days | Risk of pulmonary embolism within 90 days of administering one of the drugs studied |
| 90 day risk of deep venous thrombosis | 90 days | Risk of pulmonary embolism within 90 days of administering one of the drugs studied |
| Heparin induced thrombocytopenia | 90 days | Risk of heparin induced thrombocytopenia defined by; thrombocytes less than 150 x 109/l and presence of HIT antibodies |
| Liver failure | 90 days | Risk of liver failure defined by ALAT 3X upper limit of normal |
| Length of hospital admission | Admission time (up to 1 year from inclusion measured in days) | Length of hospital admission |
| Days alive out of hospital | Time out of hospital (up to 1 year from inclusion measured in days) | Days alive out of hospital |
| 30-day all-cause mortality | 30 days | Risk of all-cause mortality within 30 days of administering one of the studied drugs |
| 365-day all-cause mortality | 365 days | Risk of all-cause mortality within 365 days of administering one of the studied drugs |
Other
| Measure | Time frame | Description |
|---|---|---|
| Antepartum bleeding | 9 months | Risk of antepartum bleeding during treatment with either of the two drugs studied |
| Postpartum bleeding | up to 365 days | Risk of postpartum bleeding during treatment with either of the two drugs studied |
| Placental complications | 9 months | Risk of placental complications (Abruptio placenta, placenta prevue) during treatment with either of the two drugs studied |
| Preeclampsia | 9 months | Risk of preeclampsia and eclampsia during treatment with either of the two drugs studied |
| Pregnancy loss | 9 months | Risk of pregnancy loss during treatment with either of the two drugs studied |
| Stillbirth | 9 months | Risk of stillbirth during treatment with either of the two drugs studied |
Countries
Denmark
Contacts
Backup ContactLars Køber, Professor, MD
Primary ContactKasper Iversen, Professor, MD
Outcome results
None listed